J Labbe Francois

Biography

an investor in and Chief Executive Officer of OTL Pharma, a Paris-based specialty pharmaceutical and orphan drug company, which achieved €14M sales in 2004, the year he sold the business to Strakan (now ProStrakan). He also serves as a board member of Transgène SA. Mr Labbé has worked for over 35 years in the pharmaceutical industry and was previously Chief Executive Officer of Parke Davis France. Prior to joining Parke Davis, Mr Labbé worked for Hoechst-Roussel for 25 years where he held various general management positions in Europe (The Netherlands, France, UK) and abroad (USA, South Africa). He became President Europe-Middle East-Africa of Hoechst-Marion-Roussel from 1995 to 1999, serving as a member of the Executive Committee of the group until its merger into Aventis. Mr Labbé has an MBA from the HEC Business School, Paris. an investor in and Chief Executive Officer of OTL Pharma, a Paris-based specialty pharmaceutical and orphan drug company, which achieved €14M sales in 2004, the year he sold the business to Strakan (now ProStrakan). He also serves as a board member of Transgène SA. Mr Labbé has worked for over 35 years in the pharmaceutical industry and was previously Chief Executive Officer of Parke Davis France. Prior to joining Parke Davis, Mr Labbé worked for Hoechst-Roussel for 25 years where he held various general management positions in Europe (The Netherlands, France, UK) and abroad (USA, South Africa). He became President Europe-Middle East-Africa of Hoechst-Marion-Roussel from 1995 to 1999, serving as a member of the Executive Committee of the group until its merger into Aventis. Mr Labbé has an MBA from the HEC Business School, Paris.

Research Interest

pharma